BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

26 articles for JL Kim

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Purinylpyridinylamino-based DFG-in/aC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.EBI
Amgen
Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.EBI
Amgen
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.EBI
Amgen
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.EBI
Amgen
Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.EBI
Amgen
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.EBI
Amgen
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.EBI
Amgen
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.EBI
Amgen
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.EBI
Vertex Pharmaceuticals
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.EBI
Vertex Pharmaceuticals
SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FORTREATMENT OF LEPTIN-RESISTANT OBESITYBDB
The Children’S Medical Center
Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulatorsBDB
Janssen Pharmaceutica
Indazole compound for use in inhibiting kinase activity, composition and application thereofBDB
Shenzhen Targetrx
Hydantoins that modulate BACE-mediated app processingBDB
Buck Institute For Research On Aging
Pyridinyl pyrazoles as modulators of RORγTBDB
Janssen Pharmaceutica
Mammalian and bacterial nitric oxide synthase inhibitorsBDB
Northwestern University
Triazolones and tetrazolones as inhibitors of ROCKBDB
Bristol-Myers Squibb
Benzazepine dicarboxamide compounds with tertiary amide functionBDB
Hoffmann-La Roche
2,4-diaminopyrimidine derivatives as histamine H4 modulatorsBDB
Janssen Pharmaceutica
Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBDB
Boehringer Ingelheim International
Synthesis, in vitro ß-glucuronidase inhibitory activity and in silico studies of novel (E)-4-Aryl-2-(2-(pyren-1-ylmethylene)hydrazinyl)thiazoles.BDB
University of Karachi
Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapyBDB
Abbvie Deutschland
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".BDB
Griffith University
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.BDB
Avenida De La Industria
Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.BDB
University of Alabama At Birmingham
Hydrophobic benzoic acids as inhibitors of influenza neuraminidase.BDB
University of Alabama At Birmingham